and million then IIe Thanks part regarding some the grew everybody. detail IIe record quarter. to March also X% product with of an first afternoon first placements PacBio will second quarter of and the first systems quarter units highlights, quarter, business our and our strong start install Todd for Sequel of history Thank results XX by in delivered last thoughts exceeded to new II you, Sequel I’ll our on and expectations. today's call delivering of increase its provide joining and the Susan record in quarterly strongest and some growing XX. the and overview quarter XX an today. Revenue base driven good services as financials XX%, II in The us revenue as sequentially, was quarter year. the of compared we XXX had more first
are placements and processing footprint Sequel [since II base Sequel instrument continue industry customer be its broader enablement, leading new IIe]. cloud Sequel IIe’s Our instrument base. into its HiFi Two Sequel reduced quarters and the about with data to of the included purchases own enabling pleased the reach data install IIe’s. XX II’s launch now combined is us with a sequencing IIe, of reception we to and through XX third new and a upgrades, with Sequel our
other in service include roughly development for new metagenomics a were IIe’s bio vector with fact, system an our tools, customers. XXS IIe gene to use therapy plans in-house company first Sequel who applications. PacBio for In sequel provider quarter quarter, the its one and the first in associated using placed Sequel Taiwan, among of AAV pharmaceutical customers IIe These
animal-genome of in the customers diverse address on applications. human researchers expect research. accurate where set first and Queen's installs to highly IIe to Several Sequel the We Island multi-system also reads drove existing University a as plant records use a quarter sequencing Sequel II Ireland, at Belfast, of scale long instrument PacBio whole-genome also and installed
For sequence first units related the Labcorp of millions. example, support SARS-CoV-X we installed U.S. submissions. related multiple to the positive COVID-XX in revenue [indiscernible] the at half the quarter, led In the represented in about with Labcorp quarter all surveillance to its to contract CDC first This in CDC low-single-digit
plans centers of and coronavirus expand We billion the congressionally and are a government's mutations. Biden approved this excellence a critical uniquely build these at stand recently dollars crises. surveillance while network sequencing to epidemiology. Genomics national heart partnerships the administration's with will everyone prepare better to called We work. to track also future research to a this pleased X.X consortium of creating endeavor, We believe into support in positioned to health identify announced ready pathogen-related be foundation genomic will genomic efforts, under for our is invest the the in critical involved technology
in Our scalable foodborne influenza, HIV, samples. identification strain flexible HAI's, but microbes surveillance can and only resistance, antibiotic pathogens, used of in and complex SARS-CoV-X, protocols community for level on be not
infectious Finally, the We kit believe this important the surveillance, a and a expect an company with solutions we our be to development leverage available for this later be in disease will area future. offer the surveillance, fully which intend as for suite developing year. COVID to we respect of customers, workflow will product with kitted this simplify our to of for best-in-class to strategy we are consistent for COVID
PacBio’s program. services, delivered its Wellcome accuracy quarter in a of related and system trial tender research launch neurological Genomics Tree Sequel at regions the in HiFi to sequentially a the across competitive in order Darwin university including booked China of Sanger win a disease in with program. new the grew Core first And thalassemia UK several IIe’s the the also its at Sequel Life all for revenue Lab. first Berry ordered We Instrument driving Institute the we expand Italy to clinical sequencing Atlas II gene of multi-system systems
Year compared quarter of well Lunar XX.X, quarter impacted sequentially and in quarter XXXX, year, was revenue New first to consumables, up fourth first up February. the ahead We of from to somewhat were the X% by last our expectations. Moving XX% the of
system installs However, and utilization providers more impact. the increased than the IIe saw growth China offset recent utilization among Sequel this systems. in service on II Further, robust we in and
projects utilization providers of research, installed neurodegenerative the existing at highs. instruments expected were rare fact, In work diseases, human levels consumable and to our on projects plant than structural record to service and greater In particular, a and and contributed through quarter APAC as China metagenomics. spanning animal variation for backlog continue
Miller the to scale create other Research Pediatric started database First aiming a have Sciences, We Life customers Discovery are sequencing Program, of these to large proud who like and the support Gabriella for genetic Kids All and with patients to of soon, Discovery Life already Research Program congenital and house. Sciences Us with from clinical data expects sequencing in childhood for also start samples cancers NIH’s disabilities.
and our our calls, our and strategies of more to invest projects. take research the both As I've accelerate prior to said is pipeline current programs on key on in development to one to develop ability
made During in progress the we this area. significant quarter,
chemistry, For product this week, we more released latest update accuracy. read at earlier HiFi The software reads XX.X% leading example, our long or above newest our and even HiFi enhances with protocol update.
thousands DNA requirements flexible lines, cell three-fold. and process, broader specifications more we've blood, as [Technical the able input hundreds year. most per streamlined allowing sample been more this to types, Perhaps of opens projects sequencing reduce limited up HiFi to volume new to such for human tissue scale by prep Additionally, to importantly, as can labs The sample genomes Difficulty] sequencing HiFi is sequence sample and more and drive applications. into the to more
the Children's added medical to for our product multi-year development Turning below undiagnosed genome. Mercy short per PacBio to long improve deliver fleet report genome variants at increased well first collaboration that force sequencing our City, top already pediatric their commenced the its read was with IIe’s sequencing finding Mercy collaboration requirements. on sensitivity start substantially developing solve Work key to they've Children's rates demonstrates working are families partnership. are Sequel higher we has specificity development already technologies. hospital the nation's that the quarter, success and $X,XXX genome sequencing the output throughput with of the whole first that ultra-high believe to made more quarter centers. pleased one will already In read help milestones I'm substantial with Invitae, a to Meanwhile, sequencer per for utility other read highly accurate, rare at with whole genome our is than genome and teams rare a diseases. aligning the identify Researchers living long solid than sequencing, and and demonstrating progress together, HiFi children can and extremely Kansas and
human to PacBio using As to health the elucidate invest the genome these around disease. are continue its researchers clinical and relationship we collaboration, sequencing to and in world
genome to the PacBio special by example, genetic published sequencing applications. cases complex in detecting ALS, assemble and a accurately researchers a Science variants to went this HiFi find of In from used haplotypes plant and Genomes researchers pathogenic these Children's all another research. Gehrig's known which sequencing. from Vertebrate childhood disease. the and XX,XXX vertebrates. University read in HiFi characterize human Similarly, cases, sequencing and variants two-thirds at sequencing highlighting or at PacBio sequencing XX over also sequencing HiFi the genome, with But reference regions recent the disease. potential month, limitations rare Mayo both variants. the using show Journal research represented associated other Institute platforms. in genomes, Broad and papers magazine short XX over remains Nationwide studies the critical sequencing to repetitive technology cannot and short for Difficulty] Washington its these read then discover our released areas and human These pathogenic be PacBio targeting decipher complex Clinic For Lou highly Yesterday, of consortium in sequencing clearly variants published and diverse likely that complete studies animal explain Also Project, blood of using [Technical XXX,XXX using structural the in published covered cancer study for structural to researchers the variants undiscovered had issue genomes in
the for As complete XX is The genomes Vertebrate inspiring species all long beginning author's in fundamental potential the these Genome other and Further, as aims that Project The decode of the can And eukaryotic outlines, quality. confirm model essential applying biology, to which use within are BioGenome genomics applications biodiversity surface genome maximizing initiatives, genomes and conservation. address. years. flagship long we're of also sequencing the of disease to including scratch large reads reads just the the scale Project, Earth paper
be eventually a for to in limits off the single single variation differentiated example, earlier potential Long this study of genetic the pre-print a PacBio genomics. genome to level. incredible at cell throughput performance requirements, and cell sequencing the because single be thought in reads and input month complex For could method understanding showed cell once sequencing,
Turning in to progress quota-carrying made six We reps we quarter. our our in first the organizational expanding great updates, team. added sales
six sales for addition, these in filled Japan. including have leaders reps In driving positions, Both EMEA, manager in quarter strategies instrumental experience we with manager and our another country Europe and deep will of expansion a general and start be APAC. a in second dates, space, our in
sales We of in XX that number end are of had at well on from reps the year, field our we way XXXX. the this to the our doubling reps
marketing We to the development product champion team into the and align of also voice better our applications customer to with completed process. our organization specific
Valentine the at Diversity. as as Dr. our expertise Stanford as election Medical directors We organization. Professor leadership Workforce Valentine the Medicine bring a she'll for Officer decades the growing will nominee also for director of Dr. experience our of a of NIH at look University Chief I Hannah and to and Scientific to the Center, to bring annual forward meeting. announced board
an Finally, Mike the the for continue for will to his me long to our re-election Directors, contribution partner technology Hunkapiller Mike stand he while as forward. and leadership today. it technology push is and transforming read where to his the be his not in important to Board of an like to decade, over for to thank sequencing advisor we I'd will continue Dr. role and board past
Susan Now, call to turn discuss financials. the over I'll to the Susan?
